MGUS
MCID: MNC006
MIFTS: 43

Monoclonal Gammopathy of Uncertain Significance (MGUS)

Categories: Blood diseases, Cancer diseases, Immune diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Monoclonal Gammopathy of Uncertain Significance

MalaCards integrated aliases for Monoclonal Gammopathy of Uncertain Significance:

Name: Monoclonal Gammopathy of Uncertain Significance 11 14
Monoclonal Gammopathy of Undetermined Significance 11 19 75 71 31 33
Mgus 11 19
Mgus - [monoclonal Gammopathy of Undetermined Significance] 33
Monoclonal Gammoglobulinopathy 33
Monoclonal Gammopathy Nos 33
Iga Gammopathy 33

Classifications:



External Ids:

Disease Ontology 11 DOID:7442
ICD10 31 D47.2
ICD11 33 45411563
UMLS 71 C0026470

Summaries for Monoclonal Gammopathy of Uncertain Significance

GARD: 19 Monoclonal gammopathy of undetermined significance (MGUS) is a condition in which an abnormal protein called monoclonal protein is detected in the blood. MGUS typically does not cause any problems, although some affected people may experience numbness, tingling or weakness. In some cases, MGUS may progress over time to certain forms of blood cancer (such as multiple myeloma, macroglobulinemia, or B-cell lymphoma). MGUS is thought to be a multifactorial condition that is likely associated with the effects of multiple genes in combination with lifestyle and environmental factors. People with MGUS are usually monitored closely to ensure that the levels of monoclonal protein do not rise and other problems do not develop.

MalaCards based summary: Monoclonal Gammopathy of Uncertain Significance, also known as monoclonal gammopathy of undetermined significance, is related to agammaglobulinemia and thrombocytopenia due to platelet alloimmunization. An important gene associated with Monoclonal Gammopathy of Uncertain Significance is MYOM2 (Myomesin 2), and among its related pathways/superpathways are NF-kappaB Signaling and Mesenchymal Stem Cells and Lineage-specific Markers. The drugs Celecoxib and Sodium fluoride have been mentioned in the context of this disorder. Affiliated tissues include bone marrow, bone and liver, and related phenotypes are immune system and hematopoietic system

Disease Ontology: 11 A blood protein disease that is characterized by the presence of an abnormal protein called monoclonal protein in the blood.

Wikipedia: 75 Monoclonal gammopathy of undetermined significance (MGUS) is a plasma cell dyscrasia in which plasma... more...

Related Diseases for Monoclonal Gammopathy of Uncertain Significance

Diseases related to Monoclonal Gammopathy of Uncertain Significance via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 522)
# Related Disease Score Top Affiliating Genes
1 agammaglobulinemia 31.1 IL6 ICOSLG CD19
2 thrombocytopenia due to platelet alloimmunization 31.0 U2AF1 ICOSLG CD19
3 immunoglobulin light chain amyloidosis 31.0 SDC1 MYOM2 IGHV4-38-2 CD38 B2M
4 anemia, autoimmune hemolytic 31.0 IL6 IGHV4-38-2 ICOSLG CD38 CD19
5 lymphoma, mucosa-associated lymphoid type 30.9 SDC1 IGHV4-38-2 ICOSLG CD19 B2M
6 chronic inflammatory demyelinating polyradiculoneuropathy 30.8 MYOM2 MAG ICOSLG
7 splenic marginal zone lymphoma 30.8 U2AF1 IGHV4-38-2 CD19
8 hypersensitivity reaction type iv disease 30.7 IL6 ICOSLG CD19
9 demyelinating polyneuropathy 30.7 MYOM2 MAG IL6
10 common variable immunodeficiency 30.6 IL6 ICOSLG CD38 CD19
11 solitary osseous plasmacytoma 30.6 SDC1 NCAM1 MYOM2 IGHV4-38-2 CD38 B2M
12 bone disease 30.5 NSD2 IL6 ICOSLG FGFR3 B2M
13 skin disease 30.5 U2AF1 NCAM1 IL6 ICOSLG FGFR3 CD19
14 leukemia, chronic myeloid 30.5 U2AF1 MIR19A IL6 ICOSLG CD38 CD19
15 waldenstroem's macroglobulinemia 30.5 SDC1 MYOM2 MAG IGHV4-38-2 CD38 CD19
16 extramedullary plasmacytoma 30.5 SDC1 NCAM1 MYOM2 IGHV4-38-2 CD38 CD19
17 lymphoplasmacytic lymphoma 30.4 SDC1 MYOM2 MAG IGHV4-38-2 CD38 CD19
18 myeloma, multiple 30.4 U2AF1 SDC1 NSD2 NCAM1 MYOM2 MIR19A
19 heavy chain disease 30.4 MYOM2 IGHV4-38-2
20 myelodysplastic syndrome 30.3 U2AF1 NCAM1 IL6 ICOSLG CD38 CD19
21 mantle cell lymphoma 30.3 U2AF1 SDC1 IL6 IGHV4-38-2 ICOSLG CD38
22 connective tissue disease 30.3 U2AF1 MIR30D MIR19A IL6 ICOSLG FGFR3
23 plasmacytoma 30.3 NCAM1 IL6 CD38 B2M
24 peripheral nervous system disease 30.2 U2AF1 NCAM1 MYOM2 MAG IL6 ICOSLG
25 gamma heavy chain disease 30.1 SDC1 IGHV4-38-2 CD38 CD19
26 plasmablastic lymphoma 30.1 SLAMF7 SDC1 IGHV4-38-2 CD38
27 exanthem 30.1 IL6 ICOSLG CD19
28 diffuse large b-cell lymphoma 30.1 U2AF1 IGHV4-38-2 ICOSLG CD19
29 pancytopenia 30.0 U2AF1 NCAM1 IL6 CD19
30 marginal zone b-cell lymphoma 30.0 U2AF1 SDC1 IGHV4-38-2 ICOSLG CD38 CD19
31 leukemia, acute lymphoblastic 30.0 U2AF1 IGHV4-38-2 ICOSLG CD38 CD19
32 leukemia, acute myeloid 29.9 U2AF1 SDC1 NCAM1 MIR30D IL6 IGHV4-38-2
33 deficiency anemia 29.9 U2AF1 IL6 ICOSLG CD38 CD19 B2M
34 leukemia, chronic lymphocytic 29.8 U2AF1 SDC1 NCAM1 MIR30D MIR19A IL6
35 smoldering myeloma 29.7 TENT5C SLAMF7 SDC1 NSD2 NCAM1 MYOM2
36 severe combined immunodeficiency 29.6 IL6 ICOSLG CD38 CD19
37 lymphoma, non-hodgkin, familial 29.6 U2AF1 SDC1 NCAM1 IL6 IGHV4-38-2 ICOSLG
38 plasma cell neoplasm 29.5 U2AF1 SDC1 NCAM1 MYOM2 IL6 IGHV4-38-2
39 bone marrow cancer 29.5 U2AF1 SLAMF7 SDC1 NSD2 NCAM1 MYOM2
40 plasma cell leukemia 29.1 TENT5C SLAMF7 SDC1 NSD2 NCAM1 MYOM2
41 light chain deposition disease 11.7
42 macroglobulinemia, waldenstrom 1 11.1
43 thrombophilia due to thrombin defect 10.6
44 vasculitis 10.6
45 nephrotic syndrome 10.5
46 axonal neuropathy 10.5
47 body mass index quantitative trait locus 11 10.5
48 agammaglobulinemia, x-linked 10.5
49 chronic neutrophilic leukemia 10.5
50 myeloproliferative neoplasm 10.5

Graphical network of the top 20 diseases related to Monoclonal Gammopathy of Uncertain Significance:



Diseases related to Monoclonal Gammopathy of Uncertain Significance

Symptoms & Phenotypes for Monoclonal Gammopathy of Uncertain Significance

MGI Mouse Phenotypes related to Monoclonal Gammopathy of Uncertain Significance:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 10 B2M CD19 CD38 DIS3 FGFR3 ICOSLG
2 hematopoietic system MP:0005397 9.77 B2M CD19 CD38 DIS3 FGFR3 ICOSLG
3 integument MP:0010771 9.28 B2M CD19 FGFR3 IL6 MAF MYOM2

Drugs & Therapeutics for Monoclonal Gammopathy of Uncertain Significance

Drugs for Monoclonal Gammopathy of Uncertain Significance (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 55)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Celecoxib Approved, Investigational Phase 2 169590-42-5 2662
2
Sodium fluoride Approved Phase 2 7681-49-4
3
Curcumin Approved, Investigational Phase 2 458-37-7, 84765-67-3 969516
4
Metformin Approved Phase 2 1115-70-4, 657-24-9 4091
5
Acetaminophen Approved Phase 2 103-90-2 1983
6
Acalabrutinib Approved, Investigational Phase 2 1420477-60-6 71226663 71226662
7
Daratumumab Approved Phase 2 945721-28-8
8
Lenalidomide Approved Phase 2 191732-72-6 216326
9
Cianidanol Approved, Withdrawn Phase 2 154-23-4 9064
10
Rituximab Approved Phase 2 174722-31-7
11
Piperine Investigational Phase 2 94-62-2 638024
12
Epigallocatechin gallate Investigational Phase 2 989-51-5 65064
13
Epigallocatechin Experimental, Investigational Phase 2 970-74-1 72277
14
Epicatechin Investigational Phase 2 490-46-0 58571364 72276
15 Vaccines Phase 2
16 Cyclooxygenase Inhibitors Phase 2
17 Cyclooxygenase 2 Inhibitors Phase 2
18 Radiopharmaceuticals Phase 2
19 Listerine Phase 2
20 Fluorodeoxyglucose F18 Phase 2
21 Fluorides Phase 2
22 Chelating Agents Phase 2
23 Antibodies, Monoclonal Phase 2
24 Analgesics Phase 2
25 Anti-Inflammatory Agents, Non-Steroidal Phase 2
26 Analgesics, Non-Narcotic Phase 2
27 Anti-Inflammatory Agents Phase 2
28 Cytochrome P-450 Enzyme Inhibitors Phase 2
29 Histamine H1 Antagonists Phase 2
30 Histamine Antagonists Phase 2
31 Immunoglobulins Phase 2
32 Antibodies Phase 2
33 Omega 3 Fatty Acid Phase 2
34 Angiogenesis Inhibitors Phase 2
35 Immunologic Factors Phase 2
36 Antirheumatic Agents Phase 2
37 Neuroprotective Agents Phase 2
38 Antioxidants Phase 2
39 Tea Phase 2
40 Protective Agents Phase 2
41 Antineoplastic Agents, Immunological Phase 2
42
Siltuximab Approved, Investigational Phase 1 541502-14-1
43
Rifaximin Approved, Investigational Phase 1 80621-81-4 46783403 6436173
44 Liver Extracts Phase 1
45
Imatinib Mesylate Phase 1 220127-57-1
46 Protein Kinase Inhibitors Phase 1
47 Anti-Bacterial Agents Phase 1
48 Anti-Infective Agents Phase 1
49 Gastrointestinal Agents Phase 1
50
Altretamine Approved Early Phase 1 645-05-6 2123

Interventional clinical trials:

(show top 50) (show all 59)
# Name Status NCT ID Phase Drugs
1 Reduction of Antigen-Lipid-Driven Monoclonal Gammopathies by Targeting Epicardial Fat and Its Lipids Content With Liraglutide: A Glucagon Like Peptide-1 Receptor Analogue (GLP-1RA) Withdrawn NCT02920190 Phase 4 Liraglutide
2 Double-blind Randomized Trial of Rituximab Versus Placebo in Polyneuropathy Associated With Anti-MAG IgM Monoclonal Gammopathy Completed NCT00259974 Phase 3 Rituximab
3 Biologic and Clinical Role of COX-2 Inhibitor (Celecoxib)in the Management of MGUS and Smoldering Myeloma Completed NCT00099047 Phase 2 celecoxib;placebo
4 A Pilot Study of Novel Imaging Modalities in Monoclonal Gammopathy of Undetermined Significance (MGUS), Smoldering Multiple Myeloma (SMM), and Multiple Myeloma (MM) Completed NCT01237054 Phase 2 18-NaF PET;18-FDG PET/CT
5 Study of High-dose Influenza Vaccine Efficacy by Repeated Dosing IN Gammopathy Patients (SHIVERING 2) Completed NCT02566265 Phase 2
6 A Single Arm, Multicenter, Phase II, Open-Label Trial to Evaluate Efficacy of Isatuximab in Patients With Monoclonal Gammopathy of Renal Significance Recruiting NCT04614558 Phase 2 Isatuximab
7 Efficacy of Curcumin and Piperine in Patients on Active Surveillance for Either Monoclonal Gammopathy of Unknown Significance (MGUS), Low-risk Smoldering Multiple Myeloma (SMM) or Early Stage Prostate Cancer: A Pilot Study Recruiting NCT04731844 Phase 2 Curcumin plus Piperine
8 A Randomized Placebo-Controlled Phase 2 Study of Metformin for the Prevention of Progression of Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma Recruiting NCT04850846 Phase 2 Metformin XR
9 Phase II Study on Acalabrutinib and Anti-CD20 Antibody in Patients With Anti-MAG Mediated Neuropathy Recruiting NCT05065554 Phase 2 Acalabrutinib;Rituximab
10 Randomized Double-Blind Phase 2 Trial of Ibrutinib Versus Standard Treatment for COVID-19 Illness Requiring Hospitalization With Safety Lead-In Active, not recruiting NCT04439006 Phase 2 Ibrutinib
11 A Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma Active, not recruiting NCT03236428 Phase 2 Daratumumab
12 Isatuximab in Type I Cryoglobulinemia: A Prospective Pilot Study Not yet recruiting NCT05114109 Phase 2 Isatuximab Injection
13 A Phase II Trial of Lenalidomide as a Treatment for Neuropathy Associated With Nonmalignant Monoclonal Gammopathy of Undetermined Significance (MGUS) Terminated NCT00665652 Phase 2 Lenalidomide
14 The Clinical and Biologic Evaluation of Polyphenon E, an Extract of Green Tea Containing EGCG, in Plasma Cell Dyscrasias - Pilot Study Terminated NCT00942422 Phase 2
15 Inhibition of Nuclear Factor Kappa B for Prevention of Disease Progression in Indolent B Cell Malignancies Terminated NCT00899353 Phase 2
16 A Phase II Trial of Rituximab for Peripheral Neuropathy Associated With Monoclonal Gammopathy of Undetermined Significance (MGUS) Terminated NCT00588822 Phase 2
17 Novel Imaging Modalities to Characterize Angiogenesis in the Bone Marrow Microenvironment in Multiple Myeloma (MM) and Its Precursor Disease Withdrawn NCT01571726 Phase 2 Fluciclatide
18 A Phase I Pharmacokinetic Study of STI571 in Patients With Advanced Malignancies and Varying Levels of Liver Dysfunction Completed NCT00025415 Phase 1 imatinib mesylate
19 A Study of Siltuximab (Anti-IL-6 Monoclonal Antibody) Effects on the QT Interval in Subjects With Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Indolent Multiple Myeloma Completed NCT01219010 Phase 1
20 Pilot Study of Oral Rifaximin in Patients With Monoclonal Gammopathy Recruiting NCT03820817 Phase 1 Rifaximin
21 A Phase I Trial to Evaluate Safety and Immunogenicity of a Cytomegalovirus Peptide Vaccine Co-Injected With PF-03512676 Adjuvant in Recipients of Allogeneic Hematopoietic Stem Cell Transplant Active, not recruiting NCT01588015 Phase 1
22 Immunologic and Genetic Characteristics of Monoclonal Immunoglobulins in Patient With Tuberculosis Unknown status NCT00173264
23 Diagnosis of Monoclonal Gammopathy of Renal Significance in Patients With Paraproteinemias Unknown status NCT03629561
24 Understanding Monoclonal Gammopathy of Unknown Significance (MGUS): A Research Study to Investigate the Functional Consequences of Paraprotein Production in MGUS Unknown status NCT02933021
25 Frequency and Characteristics of Pruritus in Patients With Monoclonal Gammopathy Completed NCT03832140
26 A Diagnostic Screening Trial Seeking AL Amyloidosis Very Early Completed NCT02741999
27 Genomic and Psychosocial Effects of the Relaxation Response Resiliency Program (3RP) on Patients With MGUS and Smoldering Multiple Myeloma Completed NCT01955395
28 S0309, Myeloma Specimen Repository Protocol, Ancillary Completed NCT00919139
29 S0120, A Prospective Observational Biologic Study of Asymptomatic Patients With Monoclonal Gammopathy and Plasmaproliferative Disorders Completed NCT00900263
30 The Development and Pilot Testing of a New Magnetic Resonance (MR) Imaging Protocol to Quantify Both Myeloma Disease Burden and Associated Bone Loss Completed NCT03951220
31 Prognostic Study of Markers of Angiogenesis and Coagulability in Patients With Monoclonal Gammopathy Completed NCT01543100
32 A Prospective Study Of Circulating Multiple Myeloma Cells As A Biomarker Of Progression In Myeloma Precursor States (MGUS And SMM) Completed NCT01958528
33 Study of Biomarkers of Exposure and Effects in Agriculture Completed NCT01139476
34 Sleep Apnea in Patients With MGUS and MM Recruiting NCT04114084
35 Screening to Improve Survival in AL Amyloidosis Recruiting NCT04615572
36 Study of Precursor Hematological Malignancies to Assess the Relationship Between Molecular Events of Progression and Clinical Outcome Recruiting NCT02269592
37 Prospective Observational Study of Clinical and Genomic Predictors of Progression to Myeloma in Asymptomatic Monoclonal Gammopathies Recruiting NCT02726750
38 A Randomized Placebo Controlled Study of a Plant-Based Dietary Versus Supplement Versus Placebo Intervention in Patients With Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Multiple Myeloma (SMM) - The Nutrition Prevention (NUTRIVENTION3) Study Recruiting NCT05640843
39 Registry for Adults With Plasma Cell Disorders (PCD's) Recruiting NCT03717844
40 Prospective Observation of the Incidence and Natural History of Monoclonal Gammopathy in Patients Undergoing Weight Reduction Surgery Recruiting NCT03855878
41 Monoclonal Gammopathy of Undetermined Significance (MGUS), Smoldering Myeloma (SMM), and Multiple Myeloma Patient Experience With COVID-19 Survey Recruiting NCT04727294
42 A Prospective Cohort Study of Patients With Plasma Cell Disorders (PCDs) in PKUFH Recruiting NCT05283993
43 Quality of Life in Patients With Asymptomatic Monoclonal Gammopathies Recruiting NCT05136807
44 A Pilot Plant-Based Dietary Intervention in Overweight and Obese Patients With Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Multiple Myeloma (SMM) - The Nutrition Prevention (NUTRIVENTION) Study Recruiting NCT04920084
45 Monoclonal Gammopathies of Renal Significance: Clinical-histological Features of a Multicenter Case Series (MGRS Project) Recruiting NCT05119309
46 Buckeye Surveillance, Contact, and Research for Multiple Myeloma and Amyloidosis Recruiting NCT01408225
47 Two Biologically and Clinically Distinct Entities: Progressive Versus Stable Multiple Myeloma (MM) Precursor Conditions (TRANSFORMM) Recruiting NCT05361694
48 Characterising Risk and Biology Of Smouldering Myeloma for Early Detection Of Symptomatic Myeloma Recruiting NCT05047107
49 Dysregulation of Glutamine Metabolism in the Pathogenesis of Multiple Myeloma Recruiting NCT03119883
50 Spanish Registry of Patients With Diagnosis of IgM-MGUS, Asymptomatic & Symptomatic Waldenström Macroglobulinemia. Analysis of Clinical and Laboratory Features, Treatment and Outcomes. Recruiting NCT05093153

Search NIH Clinical Center for Monoclonal Gammopathy of Uncertain Significance

Genetic Tests for Monoclonal Gammopathy of Uncertain Significance

Anatomical Context for Monoclonal Gammopathy of Uncertain Significance

Organs/tissues related to Monoclonal Gammopathy of Uncertain Significance:

MalaCards : Bone Marrow, Bone, Liver, Prostate, Myeloid, T Cells, B Cells

Publications for Monoclonal Gammopathy of Uncertain Significance

Articles related to Monoclonal Gammopathy of Uncertain Significance:

(show top 50) (show all 2823)
# Title Authors PMID Year
1
Diagnosing Multiple Myeloma and Related Disorders. 62
36270842 2023
2
CCL18 promotes migration and invasion of multiple myeloma cells and is associated with poor prognosis. 62
36455232 2022
3
Predictive Immune Markers for Disease Progression in Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance 62
35965418 2022
4
Successful use of lenalidomide to treat refractory acquired von Willebrand disease associated with monoclonal gammopathy. 62
36194257 2022
5
SARS-CoV-2 Infection Incidence and Outcome Before and After Full Vaccination in Patients With Monoclonal Gammopathy of Undetermined Significance. 62
36382051 2022
6
Prevalence of Monoclonal Gammopathy of Undetermined Significance in Black South African Men. 62
36126958 2022
7
Identifying monoclonal gammopathy of undetermined significance from electronic health records. 62
36464325 2022
8
Risk factors for severe infection and mortality in COVID-19 and monoclonal gammopathy of undetermined significance. 62
36096078 2022
9
Monoclonal gammopathy of undetermined significance (MGUS) characterized by refractory lower gastrointestinal postoperative bleeding with coagulopathy. 62
36457584 2022
10
Pathology of Initial Axon Segments in Chronic Inflammatory Demyelinating Polyradiculoneuropathy and Related Disorders. 62
36362407 2022
11
MGUS and clonal hematopoiesis show unrelated clinical and biological trajectories in an older population cohort. 62
35390146 2022
12
Long term follow-up of complement parameters to improve the management of acquired angioedema due to C1-inhibitor deficiency. 62
36387475 2022
13
Tubulointerstitial nephritis with IgA kappa-positive plasma cells in a patient with primary Sjögren's syndrome and monoclonal gammopathy. 62
36367665 2022
14
Diagnostics in Waldenström's macroglobulinemia: a consensus statement of the European Consortium for Waldenström's Macroglobulinemia. 62
36435884 2022
15
Emergence of proteinase 3-antineutrophil cytoplasmic antibody-associated glomerulonephritis with mesangial immune deposition during the clinical course of IgG λ monoclonal gammopathy of uncertain significance. 62
35420387 2022
16
High Dimensional Immune Profiling of Smoldering Multiple Myeloma Distinguishes Distinct Tumor Microenvironments. 62
35945129 2022
17
Plasma cell neoplasms and related entities-evolution in diagnosis and classification. 62
36414803 2022
18
Cryoglobulinemic Vasculitis Associated with Monoclonal Gammopathy of Undetermined Significance Developed after Sustained Virologic Response of Hepatitis C: A Case Report. 62
36384905 2022
19
Prospective Multireader Evaluation of Photon-counting CT for Multiple Myeloma Screening. 62
36399038 2022
20
Acquired von Willebrand syndrome and lymphoid neoplasms: A review of malignancy management, and propositions of practical recommendations. 62
36006003 2022
21
Co-occurrence of Three Systemic Diseases: ANCA-associated Vasculitis, Sjögren's syndrome and Sarcoidosis. 62
36450474 2022
22
Cancer risk and gammopathies in 2123 adults with Gaucher disease type 1 in the International Gaucher Group Gaucher Registry. 62
36054609 2022
23
IgA vasculitis with underlying monoclonal IgA gammopathy: innovative therapeutic approach targeting plasma cells. A case series. 62
35713822 2022
24
Coexistence of Post-essential Thrombocythemia Myelofibrosis With Monoclonal Gammopathy of Undetermined Significance: A Case Report. 62
36348874 2022
25
The OTUD6B-LIN28B-MYC axis determines the proliferative state in multiple myeloma. 62
36059274 2022
26
The immune system in multiple myeloma and precursor states: Lessons and implications for immunotherapy and interception. 62
36194782 2022
27
An Analysis of M-protein in Plasma cell Dyscrasia Patients Identifies that IgG Lambda Subtype is More Commonly Associated with Normal Serum Free Light Chain (SFLC) Ratio. 62
36262785 2022
28
Alternative Complement Pathway Inhibition With Iptacopan for the Treatment of C3 Glomerulopathy-Study Design of the APPEAR-C3G Trial. 62
36217526 2022
29
Unraveling unique features of plasma cell clones in POEMS syndrome with single-cell analysis. 62
36129760 2022
30
Anti-myelin-associated-glycoprotein neuropathy successfully treated with tirabrutinib. 62
36247137 2022
31
Prognostic impact of MYD88 and CXCR4 mutations assessed by droplet digital polymerase chain reaction in IgM monoclonal gammopathy of undetermined significance and smouldering Waldenström macroglobulinaemia. 62
36210485 2022
32
Monoclonal Gammopathies in a Fracture Liaison Service. 62
36173906 2022
33
Diagnostic relevance of 2-[18 F]-FDG PET/CT in patients recently diagnosed with monoclonal gammopathy of undetermined significance. 62
36222822 2022
34
Cardiovascular Associations With Monoclonal Gammopathy of Undetermined Significance: Real or Coincidental? 62
36213348 2022
35
Concurrent Monoclonal Gammopathy of Undetermined Significance in a Patient With Maxillary Sinus Fungus Ball. 62
36053198 2022
36
Prevalence of monoclonal gammopathy of undetermined significance in US black women. 62
35723873 2022
37
Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: Results of the iStopMM study. 62
36100605 2022
38
Characterizing M-protein light chain glycosylation via mass spectrometry. 62
36113628 2022
39
IgM monoclonal gammopathies of clinical significance: diagnosis and management. 62
35770530 2022
40
Correlation of plasma cell assessment by phenotypic methods and molecular profiles by NGS in patients with plasma cell dyscrasias. 62
36138464 2022
41
Steps towards a Multiple Myeloma Cure? 62
36143236 2022
42
Smoldering multiple myeloma current treatment algorithms. 62
36064707 2022
43
Cardiovascular Morbidity in Monoclonal Gammopathy of Undetermined Significance: A Danish Nationwide Study. 62
36213365 2022
44
Revisiting the spectrum of IgM-related neuropathies in a large cohort of IgM monoclonal gammopathy. 62
35505107 2022
45
Agent Orange Exposure, Transformation From MGUS to Multiple Myeloma, and Outcomes in Veterans. 62
36426111 2022
46
Genome-wide profiling of 5-hydroxymethylcytosines in circulating cell-free DNA reveals population-specific pathways in the development of multiple myeloma. 62
35974364 2022
47
[Expression of miR-17-5p in the plasma of patients with multiple myeloma and its role in tumorigenesis and development]. 62
35970794 2022
48
A case of type I cryoglobulinaemia vasculitis associated with monoclonal gammopathy of undetermined significance exacerbated by a progression to multiple myeloma. 62
35482531 2022
49
Calorimetric Markers for Detection and Monitoring of Multiple Myeloma. 62
36010876 2022
50
Efficacy of SARS-CoV-2 vaccination in patients with monoclonal gammopathies: A cross sectional study. 62
35961779 2022

Variations for Monoclonal Gammopathy of Uncertain Significance

Copy number variations for Monoclonal Gammopathy of Uncertain Significance from CNVD:

6
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 13350 1 1 125000000 Gain Monoclonal gammopathy of undetermined significance
2 16482 1 125000000 249250621 Gain Monoclonal gammopathy of undetermined significance
3 55476 11 53700000 135006516 Gain Monoclonal gammopathy of undetermined significance
4 76533 13 32200000 40100000 Deletion NBEA Monoclonal gammopathy of undetermined significance
5 82835 14 17600000 107349540 Loss Monoclonal gammopathy of undetermined significance
6 89754 15 19000000 102531392 Gain Monoclonal gammopathy of undetermined significance
7 124088 19 1 26500000 Gain Monoclonal gammopathy of undetermined significance
8 166137 3 1 91000000 Gain Monoclonal gammopathy of undetermined significance
9 214491 6 61000000 171115067 Loss Monoclonal gammopathy of undetermined significance
10 253951 9 49000000 141213431 Gain Monoclonal gammopathy of undetermined significance

Expression for Monoclonal Gammopathy of Uncertain Significance

Search GEO for disease gene expression data for Monoclonal Gammopathy of Uncertain Significance.

Pathways for Monoclonal Gammopathy of Uncertain Significance

Pathways related to Monoclonal Gammopathy of Uncertain Significance according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 12.14 NCAM1 CD38 CD19 B2M
2 11.54 SDC1 NCAM1 IL6 CD19
3 11.33 NCAM1 IL6 CD38 CD19
4 11.11 SLAMF7 IL6 ICOSLG CD19
5 11.09 SDC1 NCAM1 IL6 CD38 CD19

GO Terms for Monoclonal Gammopathy of Uncertain Significance

Cellular components related to Monoclonal Gammopathy of Uncertain Significance according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 9.44 SLAMF7 SDC1 NCAM1 IGHV4-38-2 ICOSLG CD19

Sources for Monoclonal Gammopathy of Uncertain Significance

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....